search

Active clinical trials for "Digestive System Neoplasms"

Results 171-180 of 288

Outcomes of Side-to-end Versus End-to-end Colorectal Anastomosis in Non-emergent Sigmoid and Rectal...

Gastrointestinal Neoplasms

Introduction: Cancer rectum and sigmoid is increasing nowadays. Resection and anastomosis is done laparoscopic approach with various techniques of anastomosis. Aim of this study: to compare between open side to end colorectal anastomosis versus laparoscopic end to end colorectal anastomosis in Non-emergent colo- rectal Cancers in adults as regard anastomotic leak, intestinal function and quality of life. Patients and Methods: Randomized controlled trial was performed on patients with Non-emergent colo rectal cancers between September 2016 and September 2018.

Completed11 enrollment criteria

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes...

Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8170 more

This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and more to measure value and quality in cancer care. This trial may show whether at-home monitoring programs can improve the care of patients after hospital discharge from surgery.

Active6 enrollment criteria

Gradual Versus Immediate Goal-dose Enteral Nutrition in Abdominal Surgery Patients

Enteral NutritionPostoperative Period1 more

Patients will be randomized to Gradual or immediate Goal-dose EN group at day 3 after abdominal surgery. Patients will receive Goal-dose EN gradually or immediately after abdominal surgery. Both groups will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital. The primary and secondary outcomes will be collected.

Completed40 enrollment criteria

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

MetastasesNeoplasm11 more

MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon. When DOX is added to MTCs, DOX attaches to the carbon part of the MTCs. MTC-DOX is directed to and deposited in the area of a tumor, where it is thought that it then "leaks" through the blood vessel walls. Once in the surrounding tissues, it is thought that Doxorubicin becomes "free from" the magnetic beads and will then be able to act against the tumor cells. The iron component of the particle has magnetic properties, making it possible to direct MTC-DOX to specific tumor sites in the liver by placing a magnet on the body surface. It is hoped that MTC-DOX used with the magnet may target the chemotherapy drug directly to liver tumors and provide a treatment to patients with cancers that have spread to the liver.

Completed13 enrollment criteria

A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas...

Gastrointestinal NeoplasmsPancreatic Neoplasms

Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Involved-field irradiation using 4-15 MV photons; plus Gemcitabine, NSC-613327.

Completed39 enrollment criteria

Prospective Study on the Value of Subcutaneous Drains in Gastrointestinal Surgery

Digestive System Diseases [C06]Digestive System Neoplasms [C04.588.274]

The aim of the study is to determine wether subcutaneus suction drain (type redon-drain) protect against surgical side infection by laparotomy in general surgery.

Completed7 enrollment criteria

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting...

Malignant Digestive System NeoplasmNausea and Vomiting

This randomized pilot clinical trial dolasetron mesylate and dexamethasone with or without aprepitant in preventing nausea and vomiting in patients undergoing oxaliplatin-containing chemotherapy for gastrointestinal malignancy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. It is not yet known whether giving aprepitant together with dolasetron mesylate and dexamethasone is more effective than dolasetron mesylate and dexamethasone alone in preventing nausea and vomiting.

Terminated18 enrollment criteria

Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary...

Digestive System NeoplasmsThoracic Neoplasms

The aim of this study is to test whether a short educational intervention about emotional skills can improve survivor cancer patient emotional skills and quality of life. Half of participants will follow the educational intervention about emotional skills, while the other half will practice relaxation followed by a non-directive talking group. The educational intervention should give better results on patient emotional skills and quality of life than the control group.

Terminated10 enrollment criteria

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl...

Gastrointestinal Neoplasms; EsophagealStomach2 more

The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.

Terminated21 enrollment criteria

Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress...

AnxietyDepression5 more

This randomized pilot clinical trial studies the effects of meditation-based breathing training on patients' control of their breathing patterns and breathing-related movement, as well as on their psychological distress and treatment experience during radiation therapy. Meditation-based breathing training may decrease breathing-related movement and the amount of stress by improving breathing patterns in patients with abdominal or lung cancer undergoing radiation therapy.

Terminated16 enrollment criteria
1...171819...29

Need Help? Contact our team!


We'll reach out to this number within 24 hrs